Final results of the OCEAN(a)-DOSE trial – published in the New England Journal of Medicine – showed that the small, interfering RNA (siRNA) drug reduced Lp(a) levels compared to placebo at ...

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk ...

Risk Stratification Using Tree-Based Models for Recurrence-Free Survival in Breast Cancer In patients with mRCC, Medicare was associated with significantly better survival outcomes compared with ...

ASCO-GI in January, SITC in the fall, ESMO and ESMO-GI. And we detail the most influential peer reviewed journals, including Nature Medicine, JCO, Journal of Clinical Oncology and Cancer Discovery.

Coherus BioSciences, Inc. reported a 4% increase in annual net revenue for 2024, reaching $267.0 million, driven by a 62% rise in UDENYCA® net revenue and a 29% increase in LOQTORZI® sales.

Background: Thioredoxin reductase (Trx) has been implicated in activation of hypoxia-inducible factor-1α, which is overexpressed in > 85% of renal cell carcinomas (RCCs). We evaluated the safety ...

After hours: March 14 at 7:40:58 PM EDT Loading Chart for SUN ...

After hours: March 14 at 4:05:10 PM EDT Loading Chart for GLP ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...

New clinical research from the Helix Research Network TM showcases how genomics improves risk identification, care adherence and precision medicine implementation The HRN is the largest and fastest ...